Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Candel Therapeutics, Inc. (CADL)

Candel Therapeutics Q2 net loss widens to $38.9 million from $4.8 million

Negative Impact 4 of 5 earnings Written later

Candel Therapeutics reported a second-quarter 2026 net loss of $38.9 million, up from $4.8 million a year earlier, as research and development and general and administrative expenses rose and warrant liability fair value changes added $12.2 million of other expense. The company said its $201.6 million in cash and cash equivalents as of June 30, 2026, is expected to fund operations into the first quarter of 2028, and it plans to submit a BLA for aglatimagene in localized prostate cancer in the fourth quarter of 2026.

Key points

  • Q2 2026 net loss was $38.9 million, or $0.52 per share, versus a net loss of $4.8 million, or $0.09 per share, in Q2 2025
  • R&D expenses rose to $19.8 million from $7.0 million, and G&A expenses rose to $6.9 million from $4.2 million
  • Cash and cash equivalents were $201.6 million at June 30, 2026, compared with $119.7 million at December 31, 2025
  • Planned BLA submission for aglatimagene in localized prostate cancer is expected in Q4 2026

The filing

CompanyCandel Therapeutics, Inc. (CADL)
Form8-K, current report
Filed with the SECAug 13, 2026, 8:15 AM ET
Accession number0001193125-26-347957

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:45 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.